top of page


Pfizer and Blackstone agree up to $1.5 billion in development funding for monthly GLP-1 obesity candidate berobenatide
Pfizer and Blackstone Life Sciences have agreed a development co-funding arrangement of up to $1.5 billion for investigational once-monthly GLP-1 therapy berobenatide, sharing clinical development risk while Pfizer retains control of the programme.

nuaxia
4 days ago2 min read


Teva targets $6–7 billion in innovative medicines revenue by 2030 as it outlines expanded R&D strategy
Teva has unveiled an expanded innovative-medicines strategy targeting $6–7 billion in annual revenue by 2030, supported by seven late-stage pipeline assets, potential annual launches and a broader R&D investment programme.

nuaxia
5 days ago2 min read


Edesa Biotech licenses paridiprubart to Kyorin in Japan for up to $146 million plus royalties
Edesa Biotech has licensed Japanese development and commercialisation rights to its investigational anti-TLR4 antibody paridiprubart to Kyorin Pharmaceutical in an agreement worth up to $146 million in stated payments plus royalties.

nuaxia
6 days ago2 min read


UK MHRA issues new guidance on accepting non-OECD safety data for clinical trial applications
The UK Medicines and Healthcare products Regulatory Agency has published new guidance allowing case-by-case assessment of certain non-clinical safety data generated outside the OECD Mutual Acceptance of Data framework for clinical trial applications.

nuaxia
Nov 62 min read


Rhythm expands LG Chem bivamelagon obesity licence to $855 million and revises royalties
Rhythm Pharmaceuticals has substantially expanded its existing bivamelagon licensing agreement with LG Chem, increasing potential deal consideration to $855 million while securing revised royalty economics across specified MC4R therapies.

nuaxia
Nov 52 min read


AbbVie licenses Nxera oral inflammatory bowel disease drug in agreement worth up to $1.47 billion
AbbVie has secured exclusive worldwide rights to Nxera Pharma's investigational oral EP4 receptor agonist NXE0033744 for inflammatory bowel disease in a licensing agreement potentially worth $1.47 billion.

nuaxia
Nov 52 min read


Biossil acquires Theriva antibiotic-degrading enzyme portfolio with up to $91 million in milestones
Biossil Labs has acquired Theriva Biologics' antibiotic-degrading enzyme portfolio, including Phase IIb-stage ribaxamase, in an asset transaction carrying up to $91 million in contingent milestones.

nuaxia
Nov 42 min read


Novartis terminates BioArctic BrainTransporter neuroscience collaboration after discontinuing antibody programme
Novartis has terminated its neuroscience collaboration with BioArctic following discontinuation of the underlying antibody programme, ending a BrainTransporter licensing arrangement established in August 2025.

nuaxia
Nov 42 min read


Menarini Stemline licenses Georgiamune GIM-621 oral cancer immunotherapy in deal worth up to $1.1 billion
Menarini's Stemline Therapeutics has secured worldwide rights to Georgiamune's investigational oral cancer immunotherapy GIM-621 in a licensing agreement worth up to $1.1 billion.

nuaxia
Oct 232 min read


OpenAI acquires Orchestra Bio to expand AI-powered drug development capabilities
OpenAI has acquired Orchestra Bio to strengthen its life-sciences AI capabilities and develop agent-based workflows for pharmaceutical research and development.

nuaxia
Oct 222 min read


Roche signs Hansoh Pharma oncology ADC collaboration with more than $15 billion in potential milestones
Roche and Hansoh Pharma have signed a major oncology licensing agreement involving antibody-drug conjugates, with more than $15 billion in potential milestone payments.

nuaxia
Oct 202 min read


Novotech agrees acquisition of Agilex Biolabs to expand bioanalytical capabilities in Australia
Novotech has agreed to acquire Agilex Biolabs, adding specialist bioanalytical laboratory capabilities to its Australian clinical-development platform.

nuaxia
Oct 21 min read


Sanofi and Regeneron expand immunology alliance in deal worth up to $8bn
Sanofi and Regeneron have expanded their long-running immunology alliance with four next-generation antibody programmes in a deal worth up to $8 billion.

nuaxia
Oct 22 min read


Novartis licenses BoomRay radioligand therapy in deal worth up to $900m
Novartis has secured exclusive worldwide rights to an undisclosed preclinical radioligand therapy from BoomRay Pharma in a licensing agreement worth up to $900 million.

nuaxia
Sep 232 min read


EMA opens consultation on new guideline for gastrointestinal drug-interaction studies
The European Medicines Agency has opened consultation on a draft guideline addressing the design and interpretation of studies assessing drug absorption interactions within the gastrointestinal tract.

nuaxia
Sep 162 min read


FDA pushes faster generic drug development with 55 new product-specific guidances
The latest regulatory package is intended to reduce uncertainty, development costs and delays for generic manufacturers as the US government increases pressure to bring lower-cost medicines to patients more quickly.

nuaxia
Aug 282 min read


Haisco licenses obesity drug HSK47388 to new US biotech in deal worth up to $1.12 billion
The agreement gives a newly formed company backed by Population Health Partners and ARCH Venture Partners ex-China rights to Haisco’s Phase II-ready oral THR-β agonist for obesity and metabolic disorders.

nuaxia
Aug 273 min read


FDA grants Fast Track designation to Phanes’ spevatamig for first-line metastatic pancreatic cancer
The designation broadens regulatory support for the CLDN18.2 × CD47 bispecific antibody as Phanes advances its chemotherapy combination through Phase II development in metastatic pancreatic ductal adenocarcinoma.

nuaxia
Aug 192 min read


FDA accepts UroGen’s UGN-103 NDA for recurrent low-grade intermediate-risk bladder cancer
The submission seeks approval for a next-generation mitomycin formulation designed for intravesical treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, building on the same drug-delivery platform as FDA-approved Zusduri.

nuaxia
Aug 182 min read


Sentynl secures option for US alvelestat rights in Phase III-ready AATD lung disease programme
The agreement gives Zydus subsidiary Sentynl Therapeutics an option for exclusive US commercial and global manufacturing rights to Mereo BioPharma’s oral neutrophil elastase inhibitor, with Mereo leading preparations for pivotal development.

nuaxia
Aug 143 min read
bottom of page